ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,406 | -24.7% | 40,000 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $1,868 | +61.9% | 40,000 | +33.3% | 0.00% | +33.3% |
| Q1 2023 | $1,154 | -14.6% | 30,000 | 0.0% | 0.00% | -25.0% |
| Q4 2022 | $1,351 | -99.9% | 30,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,210,000 | -49.7% | 30,000 | -25.7% | 0.00% | -42.9% |
| Q2 2022 | $2,405,000 | -18.5% | 40,360 | -2.4% | 0.01% | 0.0% |
| Q1 2022 | $2,951,000 | -13.8% | 41,360 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $3,425,000 | +13.6% | 41,360 | +18.5% | 0.01% | 0.0% |
| Q3 2021 | $3,014,000 | +85.6% | 34,910 | +106.4% | 0.01% | +60.0% |
| Q2 2021 | $1,624,000 | -14.4% | 16,910 | 0.0% | 0.01% | -16.7% |
| Q1 2021 | $1,898,000 | -23.3% | 16,910 | 0.0% | 0.01% | -33.3% |
| Q4 2020 | $2,475,000 | +58.9% | 16,910 | -8.3% | 0.01% | +28.6% |
| Q3 2020 | $1,558,000 | +45.2% | 18,450 | -26.9% | 0.01% | 0.0% |
| Q3 2019 | $1,073,000 | -79.2% | 25,250 | -69.6% | 0.01% | -73.1% |
| Q2 2019 | $5,151,000 | +513.2% | 83,000 | +315.0% | 0.03% | +333.3% |
| Q4 2018 | $840,000 | -59.3% | 20,000 | -51.1% | 0.01% | -57.1% |
| Q1 2018 | $2,062,000 | +44.2% | 40,920 | +75.5% | 0.01% | +27.3% |
| Q4 2017 | $1,430,000 | 0.0% | 23,320 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,430,000 | -0.9% | 23,320 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $1,443,000 | -8.0% | 23,320 | 0.0% | 0.01% | -21.4% |
| Q1 2017 | $1,569,000 | -20.8% | 23,320 | -16.2% | 0.01% | -33.3% |
| Q4 2016 | $1,981,000 | -16.8% | 27,820 | -19.9% | 0.02% | -19.2% |
| Q3 2016 | $2,381,000 | -19.9% | 34,720 | -41.9% | 0.03% | -23.5% |
| Q2 2016 | $2,971,000 | +180.0% | 59,720 | +222.5% | 0.03% | +161.5% |
| Q1 2016 | $1,061,000 | -52.3% | 18,520 | -5.8% | 0.01% | -48.0% |
| Q4 2015 | $2,223,000 | +27.8% | 19,670 | +8.9% | 0.02% | +19.0% |
| Q3 2015 | $1,739,000 | -0.1% | 18,060 | +6.2% | 0.02% | 0.0% |
| Q2 2015 | $1,741,000 | +71.0% | 17,000 | +3.7% | 0.02% | +61.5% |
| Q1 2015 | $1,018,000 | – | 16,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |